Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


7 - 9 November 2017
Austria Trend Eventhotel Pyramide,

Increase half-life and minimise manufacturing costs through new data, case studies and technologies for peptide therapeutics

Thank you to everyone who attended this year's conference

Thank you for attending EuroPEPTIDES

The EuroPEPTIDES team would like to extend a huge thank you to the 260+ oligonucleotide and peptide experts who joined us in Berlin in November. 

Across 4 days attendees benefited from exposure to new data, case studies and technologies to increase half life and minimise manufacturing costs for peptide therapeutics. Additionally, networking opportunities were plentiful with over 130 meetings being organised via the conference app.

Mark your calendar

Next year we will be in our new location of Austria on 7-9 November 2017, for more information please email

Advance your Peptide Therapeutics towards Commercial Success

Decision Makers
Companies from the Oligonucleotide and Peptide Industry
Buyer: Seller Ratio

With Thanks to the EuroPeptides 2016 Scientific Advisory Board:

  • Waleed Danho, Former, Distinguished Research Leader, Roche, USA
  • Jesper Lau, Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk, Denmark
  • Joel Richard, Senior Vice President, Peptides - Head of CMC Development, Ipsen, France
  • Matthias Urmann, Associate Vice President, Research & Translational Medicine, Insulin & Peptides, R&D, Diabetes Division, Sanofi-Aventis Deutschland GmbH, Germany
  • Bruce Morimoto, Executive Director, Applied Translational Medicine, Celerion, USA
  • Silke Wetzenstein, Chemische Einkäuferin, Bachem AG, Switzerland
  • Neil Thompson, Director, Business Development Europe, PolyPeptide Group
  • Lutz Jermutus, Senior Director, R&D & Product Development Team Leader, Cardiovascular & Metabolic Diseases iMED, MedImmune Ltd, UK
  • Paul Watt, Chief Scientific Officer, Phylogica Ltd., Australia